Long-term Riociguat Treatment in PAH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 12-Week Phase III PATENT-1 Study and PATENT-2 Open-Label Extension

被引：4
|
作者：
Meyer, Gisela [1 ]
Galie, Nazzareno [1 ]
Grimminger, Friedrich [1 ]
Gruenig, Ekkehard [1 ]
Humbert, Marc [1 ]
Jing, Zhi-Cheng [1 ]
Keogh, Anne M. [1 ]
Langleben, David [1 ]
Rubin, Lewis J. [1 ]
Fritsch, Arno [1 ]
Davie, Neil [1 ]
Ghofrani, Hossein-Ardeschir [1 ]
机构：
[1] Complexo Hosp Santa Casa Porto Alegre, Ctr Hipertensao Pulm, Porto Alegre, RS, Brazil
来源：
CHEST | 2014年 / 145卷 / 03期
关键词：
D O I：
10.1378/chest.1824389
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
513A
引用
收藏
页数：3
相关论文
共 42 条
  • [1] Long-term Riociguat Treatment in Inoperable and Persistent/Recurrent CTEPH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 16-Week Phase III CHEST-1 Study and CHEST-2 Open-Label Extension
    Wang, Chen
    D'Armini, Andrea M.
    Ghofrani, Hossein-Ardeschir
    Grimminger, Friedrich
    Hoeper, Marius M.
    Jansa, Pavel
    Kim, Nick H.
    Simonneau, Gerald
    Torbicki, Adam
    Wilkins, Martin
    Fritsch, Arno
    Davie, Neil
    Mayer, Eckhard
    CHEST, 2014, 145 (03)
  • [2] Riociguat For The Treatment Of Pulmonary Arterial Hypertension (pah): A Phase Iii Long-Term Extension Study (patent-2)
    Rubin, L. J.
    Galie, N.
    Grimminger, F.
    Grunig, E.
    Humbert, M. J. C.
    Jing, Z. -C.
    Keogh, A. M.
    Langleben, D.
    Fritsch, A.
    Kilama, M. Ochan
    Neuser, D.
    Ghofrani, H. -A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [3] Riociguat for the Treatment of Pulmonary Arterial Hypertension (PAH): 1-Year Results from the PATENT-2 Long-term Extension Study
    Rubin, Lewis
    Galie, Nazzareno
    Grimminger, Friedrich
    Gruenig, Ekkehard
    Humbert, Marc
    Jing, Zhi-Cheng
    Keogh, Anne
    Langleben, David
    Fritsch, Arno
    Menezes, Flavia
    Neuser, Dieter
    Ghofrani, Hossein
    CHEST, 2013, 144 (04)
  • [4] RIOCIGUAT FOR THE TREATMENT OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH): RESPONDER ANALYSIS OF WHO FUNCTIONAL CLASS II PATIENTS FROM THE PATENT-1 STUDY
    E, Gruenig
    Sikirica, M.
    Curram, J.
    Davie, N.
    Ghofrani, H. A.
    VALUE IN HEALTH, 2013, 16 (07) : A513 - A513
  • [5] Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial
    Ghofrani, Hossein-Ardeschir
    Grimminger, Friedrich
    Gruenig, Ekkehard
    Huang, Yigao
    Jansa, Pavel
    Jing, Zhi-Cheng
    Kilpatrick, David
    Langleben, David
    Rosenkranz, Stephan
    Menezes, Flavia
    Fritsch, Arno
    Nikkho, Sylvia
    Humbert, Marc
    LANCET RESPIRATORY MEDICINE, 2016, 4 (05): : 361 - 371
  • [6] Effects of riociguat in treatment-naive versus pretreated patients with pulmonary arterial hypertension (PAH): 1-year results from the PATENT-2 long-term extension (LTE) study
    Jansa, P.
    Galie, N.
    Ghofrani, H. A.
    Humbert, M.
    Keogh, A. M.
    Langleben, D.
    Rubin, L. J.
    Vizza, D.
    Wang, C.
    Hoeper, M.
    EUROPEAN HEART JOURNAL, 2014, 35 : 10 - 10
  • [7] Reduction in NT-proBNP and its correlation with survival in patients with PAH treated with riociguat: 2-year results from the PATENT-2 long-term extension study
    Hoeper, M. M.
    Galie, N.
    Ghofrani, H. -A.
    He, J.
    Huang, Y.
    Langleben, D.
    Zhou, D.
    Nikkho, S.
    Fritsch, A.
    Torbicki, A.
    EUROPEAN HEART JOURNAL, 2015, 36 : 708 - 708
  • [8] Efficacy of long-term (104-week) treatment with apremilast in patients with psoriatic arthritis: Results from a phase III, randomized, controlled trial and open-label extension
    Edwards, Christopher
    Blanco, Francisco
    Crowley, Jeffrey
    Hu, Chia Chi
    Shah, Kamal
    Birbara, Charles
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB248 - AB248
  • [9] Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial
    Petersenn, S.
    Salgado, L. R.
    Schopohl, J.
    Portocarrero-Ortiz, L.
    Arnaldi, G.
    Lacroix, A.
    Scaroni, C.
    Ravichandran, S.
    Kandra, A.
    Biller, B. M. K.
    ENDOCRINE, 2017, 57 (01) : 156 - 165
  • [10] Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial
    S. Petersenn
    L. R. Salgado
    J. Schopohl
    L. Portocarrero-Ortiz
    G. Arnaldi
    A. Lacroix
    C. Scaroni
    S. Ravichandran
    A. Kandra
    B. M. K. Biller
    Endocrine, 2017, 57 : 156 - 165
12345